AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P32
Within normal range
vs 3Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -1.73% |
| Q3 2025 | 118.75% |
| Q2 2025 | -58.39% |
| Q1 2025 | 42.49% |
| Q4 2024 | -34.87% |
| Q3 2024 | -31.79% |
| Q2 2024 | -17.10% |
| Q1 2024 | -1.77% |
| Q4 2023 | 3.40% |
| Q3 2023 | 6.58% |
| Q2 2023 | 12.96% |
| Q1 2023 | 36.94% |
| Q4 2022 | 3.84% |
| Q3 2022 | 25.83% |
| Q2 2022 | 18.91% |
| Q1 2022 | -3.08% |
| Q4 2021 | 8.74% |
| Q3 2021 | 30.37% |
| Q2 2021 | 148.64% |
| Q1 2021 | 0.00% |